Oculis Holding AG (OCS) Net Income towards Common Stockholders (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Net Income towards Common Stockholders of -$37.1 million in Q1 2026, down 151.01% quarter-over-quarter from $72.7 million in Q4 2025, and little changed on a YoY basis from -$37.3 million in Q1 2025.
Oculis Holding AG (OCS) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Oculis Holding AG's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$37.1 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders changed 0.46% year-over-year to -$37.1 million; the TTM figure through Mar 2026 stood at -$21.0 billion (up 9.94% YoY), while the FY2025 annual figure was -$124.3 million, down 26.45% from the prior year.
- Net Income towards Common Stockholders was -$37.1 million for Q1 2026 at Oculis Holding AG, down from $72.7 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $72.7 million in Q4 2025 to a low of -$23.3 billion in Q3 2024.
- Historically, Net Income towards Common Stockholders has averaged -$2.8 billion across 5 years, with a median of -$21.5 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders slumped 116344.35% in 2024, then surged 318.67% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$9.6 million in 2022, then plunged by 47.68% to -$14.1 million in 2023, then sank by 135.51% to -$33.3 million in 2024, then soared by 318.67% to $72.7 million in 2025, then plunged by 151.01% to -$37.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$37.1 million (Q1 2026), $72.7 million (Q4 2025), and -$21.0 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | -37.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.09 Mn |
| Dec 31, 2025 | 72.72 Mn |
| Sep 30, 2025 | -21.04 Bn |
| Jun 30, 2025 | -30.71 Mn |
| Mar 31, 2025 | -36.93 Mn |
| Dec 31, 2024 | -33.25 Mn |
| Sep 30, 2024 | -23.26 Bn |
| Jun 30, 2024 | -22.98 Mn |
| Mar 31, 2024 | -18.37 Mn |
| Dec 31, 2023 | -14.12 Mn |
| Sep 30, 2023 | -19.98 Mn |
| Jun 30, 2023 | -14.07 Mn |
| Mar 31, 2023 | -49.48 Mn |
| Dec 31, 2022 | -9.56 Mn |
| Sep 30, 2022 | -10.29 Mn |
| Jun 30, 2022 | -12.73 Mn |